Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-218-2 | CAS number: 561-41-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
Bacterial reverse mutation test (OECD 471):
The registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1), tested non-mutagenic (negative) in Salmonella Typhimurium TA98, TA100, TA1535, TA1537 and TA102 strains in the presence and absence of cofactor-supplemented liver S9 microsomal metabolic activation system. The test was performed according to OECD TG 471 and in compliance with the OECD Principles of Good Laboratory Practice.
In vitro mammalian chromosome aberration test (OECD 473):
The registered substance, 4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], did not induce chromosomal aberration up to the highest concentration of 0.00625 mg/ml of culture medium, either in the presence or absence of S9 metabolic activation system in CHO cells. The test was performed according to OECD TG 473 and in compliance with the OECD Principles of Good Laboratory Practice.
In vitro gene mutation test in mammalian cells:
The registered substance, i.e., 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], did not induce gene mutation at the locus of hypoxanthine-guanine phosphoribosyltransferase (Hprt) in CHO cells up to the concentration of 6.25 µg/ml, either in the presence or absence of S9 metabolic activation system. The test was performed according to the OECD TG 476 and in compliance with the OECD Principles of Good Laboratory Practice.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test using the Hprt and xprt genes)
- Version / remarks:
- Adopted: July 29 2016
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian cell gene mutation test using the Hprt and xprt genes
- Specific details on test material used for the study:
- Appearance: Violet Powder
Lot /Batch Number: KCP/FS/199/21
Purity/AI content :99.80%
Manufacturer Name: K.Patel Chemo Pharma Private Limited
Manufactured date: 26.05.2021
Expiry Date: 25.11.2022
Storage condition: Room Temperature (20 to 30oC)
Safety precautions: Standard safety precautions (gloves, mask, apron, head cap and goggles). - Target gene:
- hypoxanthine-guanine phosphoribosyltransferase (Hprt)
- Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- Source: NCCS, Pune, India
- Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system. The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat.
S9 mixture:
Glucose-6-phosphate (180 mg/ml): 1 ml
NADP (25 mg/ml): 1ml
Potassium chloride (150 mM): 1ml
S9 Fraction: 2 ml
Final Volume (ml): 5 ml
S9 Mix: 40 %
A volume of 2.5 ml S9 cofactor mix (40%) was added to 100 ml of culture medium to achieve 1 % v/v S9 in the culture medium. - Test concentrations with justification for top dose:
- Test concentrations:
0.0 (NC)
0.0(VC)
0.78 ug/ml
1.56 ug/ml
3.13 ug/ml
6.25 ug/ml
Justification:
The test concentrations were selected based on preliminary cytotoxicity tests I-II. Cytotoxicity was determined by calculating the Relative Survival (RS) values at each concentration. The test substance concentration which induced RS 10-20% was selected as the highest test concentration for this assay. In the preliminary cytotoxicity study, limiting cytotoxicity, i.e. >16% RS, was observed at 0.00625mg/ml both in the presence and absence of metabolic activation. Therefore, 0.00625 mg/ml was selected as the maximum test concentration used in the main study and three lower concentrations were included using spacing factor 2. - Vehicle / solvent:
- Dimethyl sulfoxide (DMSO)
- Untreated negative controls:
- yes
- Remarks:
- Distilled water
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- ethylmethanesulphonate
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration (single, duplicate, triplicate): Single culture per concnetration was used.
- Number of independent experiments: 1
METHOD OF TREATMENT/ EXPOSURE:
- Cell density at seeding (if applicable): 10 x 106 cells/25 cm2
- Test substance added in medium; in agar (plate incorporation); preincubation; in suspension; as impregnation on paper disk: in medium
TREATMENT AND HARVEST SCHEDULE:
- Preincubation period, if applicable:NA
- Exposure duration/duration of treatment: 4 hours
- Harvest time after the end of treatment (sampling/recovery times): Expression time: 8 days, plating for Mutation frequency: 10 days
FOR GENE MUTATION:
- Expression time (cells in growth medium between treatment and selection): 8 days
- Selection time (if incubation with a selective agent): 10 days
- Fixation time (start of exposure up to fixation or harvest of cells): ca 19 days
- Method used: agar or microwell plates for the mouse lymphoma assay.
- If a selective agent is used (e.g., 6-thioguanine or trifluorothymidine), indicate its identity, its concentration and, duration and period of cell exposure: 10 µg/ml of 6-thioguanine (6TG) was added and incubated at 37±2 °C, 5 % CO2 in a CO2 incubator for 10 days.
- Number of cells seeded and method to enumerate numbers of viable and mutants cells: Cloning efficiency (CE). At the end of the expression period, cells were trypsinised and counted. Cells were diluted to attain 100 cells /10 ml of cloning media and then plated in 60 mm culture plates in triplicate. The plates were incubated at 37±2 °C, 5 % CO2, in a CO2 incubator for 10 days.
- Criteria for small (slow growing) and large (fast growing) colonies: No
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method, e.g.: background growth inhibition; mitotic index (MI); relative population doubling (RPD); relative increase in cell count (RICC); replication index; cytokinesis-block proliferation index; cloning efficiency; relative total growth (RTG); relative survival (RS); other: Cytotoxicity was measured by calculating the Relative Survival (RS) at each concentration.
- Any supplementary information relevant to cytotoxicity:
METHODS FOR MEASUREMENTS OF GENOTOXICIY: Genotoxicity was demonstrated by calculating the Mutation frequency (MF) for each test concentration. - Evaluation criteria:
- The test chemical was considered to be clearly positive if in any of the experimental conditions examined:
a) at least one of the test concentrations exhibits a statistically significant increase compared with the concurrent negative control,
b) the increase is concentration-related when evaluated with an appropriate trend test,
c) any of the results were outside the distribution of the laboratory negative control data.
When all of these criteria are met, the test chemical is then considered able to induce gene mutations in cultured mammalian cells in this test system.
The test chemical was considered clearly negative if, in all experimental conditions examined:
a) none of the test concentrations exhibits a significant increase compared with the concurrent negative control,
b) all results are inside the distribution of the laboratory negative control data.
The test chemical is then considered unable to induce gene mutations in cultured mammalian cells in this test system. - Statistics:
- Statistical analysis was performed to assess a possible dose-dependent increase in mutation frequency using Fisher’s Exact Test (NCSS statistics software). The mutation frequency of the Test Item-treated group was compared to the solvent control groups. A trend was judged as significant whenever the p-value (probability value) was below 0.05.
- Key result
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- At 6.25 ug/ml, the RS values were 18.75% and 17.88% in the absence and presence of S9 metabolic activation system, respectively.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Solubility and precipitation and pH checks:
The was found to be soluble in dimethyl sulfoxide up to 200 mg/ml. No precipitation was observed at the tested concentration of 200 mg/ml. The pH values at the highest concentration of the Test Item in the medium were not altered after 0 and 4 hours of incubation.
Preliminary cytotoxicity test:
The test concentrations were selected based on preliminary cytotoxicity tests I-II. In the preliminary cytotoxicity test I, CHO cells were exposed to 0.0 (Distilled water), 0.0 (DMSO), 0.125, 0.25, 0.5, 1 and 2 mg/ml of test substance in the culture medium, both in the presence and absence of S9 metabolic activation system (1 % v/v S9 mix). After the 4-hour treatment, complete toxicity was observed at all the tested concentrations in the absence and presence of metabolic activation; therefore, an additional cytotoxicity assay was performed. The preliminary cytotoxicity test-II was performed with the following test concentrations: 0.0 (NC), 0.0 (VC), 0.00625, 0.0125, 0.025, 0.05 and 0.1 mg/ml in the culture medium, both in the presence and absence of metabolic activation system (1 % v/v S9 mix). Complete cytotoxicity was observed within the concentration range of 0.0125 - 2 mg/ml, both in the absence and presence of metabolic activation. Whereas moderate cytotoxicity (>16% Relative Survival [RS is cloning efficiency (CE) of cells plated immediately after treatment adjusted by any loss of cells during treatment as compared with cloning efficiency in vehicle control]) was noted at 0.00625 mg/ml either in the absence (RS: 18.24%) or presence (RS: 16.25%) of metabolic activation. - Remarks on result:
- other: Non-mutagenic
- Conclusions:
- The registered substance, i.e., 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], did not induce gene mutation at the locus of hypoxanthine-guanine phosphoribosyltransferase (Hprt) in CHO cells up to the concentration of 6.25 µg/ml of culture medium, either in the presence or absence of S9 metabolic activation system. The test was performed according to the OECD TG 476 and in compliance with the OECD Principles of Good Laboratory Practice.
- Executive summary:
The potential of 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], to induce gene mutation at the hypoxanthine-guanine phosphoribosyltransferase (Hprt) locus in cultured Chinese Hamster Ovary (CHO) cells was tested in the presence and absence of an exogenous metabolic activation system. The study was performed as per OECD Test Guideline No. 476 (Adopted: July 29 2016). Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system. The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat. The test substance was soluble in dimethyl sulfoxide (DMSO) at 200 mg/ml; therefore, DMSO was selected as the vehicle of the substance in this assay. The test concentrations were selected based on preliminary cytotoxicity tests I-II. In the initial cytotoxicity test I, CHO cells were exposed to 0.0 (Distilled water), 0.0 (DMSO), 0.125, 0.25, 0.5, 1 and 2 mg/ml of test substance in the culture medium, both in the presence and absence of S9 metabolic activation system (1 % v/v S9 mix). After the 4-hour treatment, complete toxicity was observed at all the tested concentrations in the absence and presence of metabolic activation; therefore, an additional cytotoxicity assay was performed. The preliminary cytotoxicity test-II was performed with the following test concentrations: 0.0 (NC), 0.0 (VC), 0.00625, 0.0125, 0.025, 0.05 and 0.1 mg/ml in the culture medium, both in the presence and absence of metabolic activation system (1 % v/v S9 mix). Complete cytotoxicity was observed within the concentration range of 0.0125 - 2 mg/ml, both in the absence and presence of metabolic activation. Moderate cytotoxicity (>16% Relative Survival [RS is cloning efficiency (CE) of cells plated immediately after treatment adjusted by any loss of cells during treatment as compared with cloning efficiency in vehicle control]) was noted at 0.00625 mg/ml either in the absence (RS: 18.24%) or presence (RS: 16.25%) of metabolic activation. Hence, the gene mutation study was conducted with Test Item concentrations of 0.78, 1.56, 3.13 and 6.25 µg/ml, both in the presence (1 % v/v S9 mix) and absence of metabolic activation system along with negative (distilled water), vehicle (DMSO) and positive controls (Ethylmethanesulfonate: 400 µg/ml in the absence of S9 metabolic activation, Benzo (a) pyrene: 30 µg/ml in the presence of S9 metabolic activation). Results: In the main study, cultures were exposed to the negative control, vehicle control, different concentrations of the Test Item, and positive control for 4 hours (short-term exposure) in the absence and presence of metabolic activation. In the absence of metabolic activation, the Relative Survival values were 100% (negative control), 95.45% (vehicle control), 79.43% (at 0.78 µg/ml), 66.78% (at 1.56 µg/ml), 46.53% (at 3.13 µg/ml), 18.75% (at 6.25 µg/ml) and 76.17% (at 400 µg/ml-positive control [Ehtylmethanesulfonate]). In the presence of metabolic activation, the relative survival values were 100% (negative control), 96.86% (vehicle control), 81.81% (at 0.78 µg/ml), 68.06% (at 1.56 µg/ml), 46.69% (at 3.13 µg/ml) 17.88% (at 6.25 µg/ml) and 78.30% (30 µg/ml-positive control[Benzo[a]pyrene]). No significant increase in the mutation frequency (MF) either in the absence (9.57 x 10-6, 9.36 x 10-6, 13.18 x 10-6 and 12.50 x 10-6 at 0.78 µg/ml, 1.56 µg/ml, 3.13 µg/ml and 6.25 µg/ml, respectively) or presence of metabolic activation (8.77 x 10-6, 10.4 8 x 10-6, 10.20 x10-6 and 13.19 x10-6 at 0.78 µg/ml, 1.56 µg/ml, 3.13 µg/ml and 6.25 µg/ml, respectively) was observed when compared to vehicle control (5.98 x10-6, 6.01 x10-6, absence and presence of S9, respectively).
The dose concentrations of the Test Item in dose formulation were analysed by a validated test method for all concentrations, and the observed concentrations were within the acceptable limit of linearity (R) ≥0.99, % recovery 70-110% and % RSD ≤ 10%. The positive controls (Ethylmethanesulfonate and Beno[a]pyrene in the absence and presence of metabolic activation, respectively) used in the study produced statistically significant increases in mutation frequency (231.51 x10-6, p<0.0001 [Ethylmethanesulfonate], 226.13 x10-6, p<0.0001 [Benzo(a)pyrene] in the absence and presence of metabolic activation, respectively) indicating the sensitivity of the test system to specific mutagens, and confirmed that the test conditions were appropriate and that the metabolic activation system functioned properly. Conclusion: The registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol (CAS No.: 561-41-1), did not induce a statistically significant or biologically relevant increase in the mutation frequency up to 6.26 µg/ml when compared to the vehicle control either in the presence or in the absence of S9 metabolic activation.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- The study contains experimental data of the registered substance.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosomal Aberration Test)
- Version / remarks:
- 29 July 2016
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Specific details on test material used for the study:
- Appearance: Violet powder
Batch Number/Lot Number: KCP/FS/199/21
Purity / AI Content: 98.81%
Manufactured by: K. Patel Chemopharma Pvt. Ltd.
Manufacturing date: 26.05.2021
Expiry Date: 25.05.2022 - Species / strain / cell type:
- Chinese hamster Ovary (CHO)
- Details on mammalian cell type (if applicable):
- Source: NCCS, Pune, India
- Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system.
The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat. - Test concentrations with justification for top dose:
- Test concentrations:
0.0 (NC), 0.0 (VC), 0.0015625, 0.003125, 0.00625 mg/ml
Justification:
The cytotoxicity was evaluated based on the reduction in the RICC. A Test Item concentration causing approximately 45±5% reduction in RICC compared to that of the concurrent vehicle control (i.e. 55±5% cytotoxicity) was selected as the highest test concentration for the chromosome aberration assay. At 0.00625 mg/ml, RICC decreased to 55±5% compared to vehicle control both in the presence and absence of metabolic activation; RICC values were 46.86% (cytotoxicity: 53.14% and 42,69% (cytotoxicity: 57.31%) in the absence and presence of S9 metabolic activation system, respectively. - Vehicle / solvent:
- dimethyl sulfoxide
- Untreated negative controls:
- yes
- Remarks:
- Distilled water
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- benzo(a)pyrene
- methylmethanesulfonate
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration (single, duplicate, triplicate): Single cultures were used in Phase I- III.
- Number of independent experiments: 3 (Phase I, Phase II and Phase III)
METHOD OF TREATMENT/ EXPOSURE:
- Cell density at seeding (if applicable): 1 x 106 cells/25 cm2
- Test substance added in medium; in agar (plate incorporation); preincubation; in suspension; as impregnation on paper disk: Test substance added in medium.
TREATMENT AND HARVEST SCHEDULE:
- Preincubation period, if applicable:
- Exposure duration/duration of treatment: 4 hours (Phase I-II), 24 hrs (Phase III)
- Harvest time after the end of treatment (sampling/recovery times): The cultures were harvested 24 hours after the beginning of treatment.
FOR CHROMOSOME ABERRATION AND MICRONUCLEUS:
- Spindle inhibitor (cytogenetic assays): indicate the identity of mitotic spindle inhibitor used (e.g., colchicine), its concentration and, duration and period of cell exposure: Two hours prior to harvesting, a volume of 50 µl from 0.1 mg/ml of colchicine stock was added to culture flask to achieve a final concentration of 1 µg/ml and incubated at 37 ±2 °C, 5 % CO2 in a CO2 incubator.
- If cytokinesis blocked method was used for micronucleus assay: indicate the identity of cytokinesis blocking substance (e.g. cytoB), its concentration, and duration and period of cell exposure: No
- Methods of slide preparation and staining technique used including the stain used (for cytogenetic assays): Slides were stained with freshly prepared 5 % Giemsa stain for 5 minutes and rinsed in distilled water for 2 minutes. After drying, slides were mounted using DPX mountant.
- Number of cells spread and analysed per concentration (number of replicate cultures and total number of cells scored): At least 300 well-spread metaphases per concentration (single culture) were analysed using 100x magnification for the incidence of structural aberrations.
- Criteria for scoring micronucleated cells (selection of analysable cells and micronucleus identification):
- Methods, such as kinetochore antibody binding, to characterise whether micronuclei contain whole or fragmented chromosomes (if applicable): No
- Criteria for scoring chromosome aberrations (selection of analysable cells and aberration identification): As slide preparation procedures often result in the breakage of a proportion of metaphases with loss of chromosomes, cells that contain the number of centromeres equal to the number 2n ± 2 were scored. In CHO cells, the number of centromeres equal to the modal number is 22 ± 2.
- Determination of polyploidy:
- Determination of endoreplication:
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method, e.g.: background growth inhibition; mitotic index (MI); relative population doubling (RPD); relative increase in cell count (RICC); replication index; cytokinesis-block proliferation index; cloning efficiency; relative total growth (RTG); relative survival (RS); other: Relative increase in cell count (RICC) was calculated.
- Any supplementary information relevant to cytotoxicity: - Evaluation criteria:
- Test Item was considered to be clearly positive if, in any of the experimental conditions examined:
At least one of the test concentrations exhibits a significant increase compared with the concurrent negative control,
The increase is dose-related when evaluated with an appropriate trend test,
Any of the results are outside of the distribution of the laboratory historical negative control database
Test Item was considered clearly negative if, in all experimental conditions examined:
None of the test concentrations exhibits a significant increase compared with the concurrent negative control.
There is no concentration-related increase when evaluated with an appropriate trend test.
The results are inside the distribution of the laboratory historical negative control database. - Statistics:
- Statistical analysis was performed to assess a possible dose-dependent increase of aberrant cell frequencies using Fisher’s Exact Test (NCSS statistics software). The percentage of aberrant cells from the Test Item treated group was compared to the solvent control groups. A trend is judged as significant whenever the p-value (probability value) is below 0.05.
- Key result
- Species / strain:
- Chinese hamster Ovary (CHO)
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- At 0.00625 mg/ml, cytotoxicity was 54.15% (RICC: 45.85%), 58.62 (RICC: 41.38%) and 58.37% (RICC: 41.63) in Phase I, Phase II and Phase III experiments, respectively.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not specified
- Positive controls validity:
- valid
- Additional information on results:
- Solubility, precipitation, and pH checks:
The Test Item was found to be soluble in dimethyl sulfoxide at 200 mg/ml concentration. No precipitation was observed at the concentration of 2 mg/ml. The pH of the test concentrations was unaltered after 0 and 4 hours of incubation of the test item in the culture medium.
Preliminary cytotoxicity tests:
In the preliminary cytotoxicity test I, CHO cells were exposed to 0.0 (NC), 0.0 (VC), 0.125, 0.25, 0.5, 1 and 2 mg/ml of the test substance both in the presence and absence of S9 metabolic activation (1 % v/v S9 mix). Excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.125 mg/ml, with and without S9 metabolic activation. In the preliminary cytotoxicity assay-II, CHO cells were treated with 0.0 (NC), 0.0 (VC), 0.0625, 0.0125, 0.025, 0.05 and 0.1 mg/ml of culture medium, both in the presence (1 % v/v S9 mix) and absence of metabolic activation system. In this second cytotoxicity assay, excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.0125 mg/ml, both in the presence and absence of metabolic activation. At 0.00625 mg/ml, RICC decreased to 55±5% compared to vehicle control both in the presence and absence of metabolic activation; RICC were 46.86% (cytotoxicity: 53.14% and 42,69% (cytotoxicity: 57.31%) in the absence and presence of S9 metabolic activation system, respectively. - Remarks on result:
- other: No clastogenic potential was observed
- Conclusions:
- The registered substance, 4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], did not induce chromosomal aberration up to the highest concentration of 0.00625 mg/ml of culture medium, either in the presence or absence of S9 metabolic activation system in CHO cells. The test was performed according to OECD TG 473 and in compliance with the OECD Principles of Good Laboratory Practice.
- Executive summary:
This in vitro experiment was performed to evaluate the ability of4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1] to cause structural chromosomal aberrations in cultured CHO cells in the presence and absence of an exogenous metabolic activation system (S9). The study was performed as per OECD Test Guidelines No.473 (Adopted: 29 July 2016). Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system.The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat. The substance was soluble in dimethyl sulfoxide (DMSO); therefore, DMSO was used as a vehicle of the test substance during the test. Test concentrations were selected based on preliminary cytotoxicity tests I-II. In the preliminary cytotoxicity test I, CHO cells were exposed to 0.0 (NC), 0.0 (VC), 0.125, 0.25, 0.5, 1 and 2 mg/ml of the test substance both in the presence and absence of S9 metabolic activation (1 % v/v S9 mix). Excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.125 mg/ml, with and without S9 metabolic activation. In the preliminary cytotoxicity assay-II, CHO cells were treated with 0.0 (NC), 0.0 (VC), 0.0625, 0.0125, 0.025, 0.05 and 0.1 mg/ml of culture medium, both in the presence (1 % v/v S9 mix) and absence of metabolic activation system. In this second cytotoxicity assay, excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.0125 mg/ml, both in the presence and absence of metabolic activation. At 0.00625 mg/ml, RICC decreased to 55±5% compared to vehicle control both in the presence and absence of metabolic activation; RICC were 46.86% (cytotoxicity: 53.14% and 42,69% (cytotoxicity: 57.31%) in the absence and presence of S9 metabolic activation system, respectively. Based on the cytotoxicity assay results, Phase I (short-term exposure in the absence of metabolic activation), Phase II (short-term exposure in the presence of metabolic activation) and Phase III (continuous exposure in the absence of metabolic activation) were conducted with the Test Item at the concentrations of 0.0015625, 0.003125 and 0.00625 mg/ml, along with vehicle (DMSO), negative (Distilled water) and concurrent positive controls (Methyl methanesulfonate: 20 µg/ml, without S9 mix; Benzo (a) pyrene: 30 µg/ml with S9 mix). Results: In Phase I, cultures were exposed to test substance, vehicle, and negative and positive control for 4 hours (short-term exposure) in the absence of metabolic activation. Average RICC values were 97.83 % (vehicle control), 68.85 % (at 0.0015625 mg/ml), 53.04 % (at 0.003125 mg/ml) and 45.85 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), 0.003125 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), 0.00625 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In Phase II, CHO cells were exposed to the test substance, vehicle, and negative and positive control for 4 hours (short-term exposure) in the presence of metabolic activation (1 % v/v S9 mix). Average RICC values were 96.47 % (vehicle control), 66.83 % (at 0.0015625 mg/ml), 56.34 % (at 0.003125 mg/ml) and 41.38 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), 0.003125 mg/ml (the mean % aberrant cells: 0.00%, p=1.0000), 0.00625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In Phase III, cultures were exposed to the substance, vehicle, negative and positive control for 24 hours (continuous exposure) in the absence of metabolic activation. Average RICC values were 95.27 % (vehicle control), 64.31 % (at 0.0015625 mg/ml), 52.11 % (at 0.003125 mg/ml) and 41.63 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), 0.003125 mg/ml (the mean % aberrant cells: 0.33%, p=1.0000), 0.00625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In all phases of the study, no significant reduction in RICC (cytotoxicity) and no increase in percent aberrant cells were observed in vehicle control (DMSO) either in the presence or absence of metabolic activation when compared to the negative control (distilled water). Conclusion: Based on the results of this study, it is concluded that 4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1]does not induce chromosomal aberration up to 0.00625 mg/ml of culture medium, either in the presence or absence of S9 metabolic activation system in CHO cells under the experimental conditions described.
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- Adopted on 21 July 1997 and corrected on 26 June 2020
- GLP compliance:
- yes
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Appearance : Violet Powder
Batch Number : KCP/FS/199/21
Purity : 99.80%
Manufacturer : K.Patel Chemo Pharma Private Limited
Manufacturing date: 26.05.2021
Expiry Date: 25.11.2022
Storage condition: Room Temperature (20 to 30o C). - Target gene:
- Histidine operon
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Remarks:
- Supplied by Moltox, USA
- Metabolic activation:
- with and without
- Metabolic activation system:
- Cofactor-supplemented liver S9 microsomal fraction was used. The S9 microsomal fraction was obtained from the liver of phenobarbitone and β-naphthoflavone-injected rat.
- Test concentrations with justification for top dose:
- Test concentrations:
0.0, 0.0, 0.00244, 0.00488, 0.0097656, 0.01953125, 0.0390625 mg/plate
Justification:
Test concentrations were selected based on solubility and precipitation checks and a preliminary cytotoxicity test. The following concentrations of the Test Item were tested in triplicate plates: 0.0 (Distilled water), 0.0 (DMSO), 0.0390625, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mg/plate using tester strains TA98, and TA100. In tester strains TA98 and TA100, complete inhibition of background lawn was observed at ≥ 0.15625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to the vehicle control. A substantial reduction in the revertant count and moderate inhibition of the background lawn was observed at 0.078125 mg/plate, and a slight reduction in the number of revertant colonies accompanied by a moderate inhibition of the background lawn growth was observed at 0.0390625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to vehicle control. - Vehicle / solvent:
- Dimethyl sulfoxide (DMSO)
- Untreated negative controls:
- yes
- Remarks:
- Distilled water
- Negative solvent / vehicle controls:
- yes
- Remarks:
- DMSO
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- 2-nitrofluorene
- sodium azide
- benzo(a)pyrene
- mitomycin C
- Details on test system and experimental conditions:
- NUMBER OF REPLICATIONS:
- Number of cultures per concentration (single, duplicate, triplicate): Triplicates were used.
- Number of independent experiments: Two. Trial I: Plate incorporation, Trial II: Pre-incubation
METHOD OF TREATMENT/ EXPOSURE:
- Cell density at seeding (if applicable): 1 to 2 ×109 bacteria/ml
- Test substance added in medium; in agar (plate incorporation); preincubation; in suspension; as impregnation on paper disk: Trial I: in agar, Trial II: in medium
TREATMENT AND HARVEST SCHEDULE:
- Preincubation period, if applicable: 20 min at 37 ± 2 °C
- Exposure duration/duration of treatment: 48 hours
- Harvest time after the end of treatment (sampling/recovery times): 48 hours
METHODS FOR MEASUREMENT OF CYTOTOXICITY
- Method, e.g.: background growth inhibition; mitotic index (MI); relative population doubling (RPD); relative increase in cell count (RICC); replication index; cytokinesis-block proliferation index; cloning efficiency; relative total growth (RTG); relative survival (RS); other: Cytotoxicity was detected as inhibition of the background lawn growth and/or reduction in revertant counts. - Evaluation criteria:
- The substance was deemed mutagenic if a biologically relevant increase in the mean number of revertants exceeding the threshold of twice (strains TA98, TA100 and TA102) or thrice (strains TA1535 and TA1537) the colony count of the corresponding solvent control was observed.
A dose-dependent increase was considered biologically relevant if the threshold was exceeded at more than one concentration.
A dose-dependent increase exceeding the threshold at only one concentration was judged as biologically relevant if reproduced in an independent experiment.
A dose-dependent increase in the number of revertant colonies below the threshold was regarded as an indication of a mutagenic potential if reproduced in an independent experiment. - Key result
- Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Moderate inhibition of the background lawn and slight reduction in the revertant count was observed at 0.0390625 mg/plate.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Moderate inhibition of the background lawn and slight reduction in the revertant count was observed at 0.0390625 mg/plate.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Moderate inhibition of the background lawn and slight reduction in the revertant count was observed at 0.0390625 mg/plate.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Moderate inhibition of the background lawn and slight reduction in the revertant count was observed at 0.0390625 mg/plate.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Moderate inhibition of the background lawn and slight reduction in the revertant count was observed at 0.0390625 mg/plate.
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Solubility and precipitation checks: The test substance was soluble in dimethyl sulfoxide. Slight precipitation was observed at 5 mg/plate, which was considered not to interfere with the scoring.
Preliminary cytotoxicity test:
Test concentrations were selected based on solubility and precipitation checks and a preliminary cytotoxicity test. The following concentrations of the Test Item were tested in triplicate plates: 0.0 (Distilled water), 0.0 (DMSO), 0.0390625, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mg/plate using tester strains TA98, and TA100. In tester strains TA98 and TA100, complete inhibition of background lawn was observed at ≥ 0.15625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to the vehicle control. A substantial reduction in the revertant count and moderate inhibition of the background lawn was observed at 0.078125 mg/plate, and a slight reduction in the number of revertant colonies accompanied by a moderate inhibition of the background lawn growth was observed at 0.0390625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to vehicle control. - Remarks on result:
- other: Non-mutagenic
- Conclusions:
- The registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1) tested non-mutagenic (negative) in Salmonella Typhimurium TA98, TA100, TA1535, TA1537 and TA102 strains in the presence and absence of cofactor-supplemented liver S9 microsomal metabolic activation system. The test was performed according to OECD TG 471 and in compliance with the OECD Principles of Good Laboratory Practice.
- Executive summary:
The mutagenic potential of 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1) was tested according to OECD 471 in Salmonella Typhimurium TA98, TA100, TA1535, TA1537 and TA102 tester strains both in the presence and absence of an exogenous metabolic activation system. Cofactor-supplemented rat liver S9 microsomal fraction was applied as a metabolic activation system. The test substance was dissolved in dimethyl sulfoxide (DMSO). Slight precipitation was observed at a test substance concentration of 5 mg/plate, which was considered not to interfere with the scoring. Test concentrations were selected based on the solubility and precipitation checks and a preliminary cytotoxicity test. In this pre-test, the following concentrations were assessed using triplicate plates: 0.0 (NC), 0.0 (VC), 0.0390625, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mg/plate using tester strains TA98, and TA100. In tester strain TA98 and TA100, complete inhibition of background lawn was observed at ≥ 0.15625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to the vehicle control. Furthermore, a substantial reduction in the revertant count and moderate inhibition of the background lawn was observed at 0.078125 mg/plate, and a slight reduction in the number of revertant colonies accompanied by a moderate inhibition of the background lawn growth was observed at 0.0390625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to vehicle control. Hence, in the mutagenicity test, the following concentrations were applied: 0.0 (NC, distilled water), 0.0 (VC, DMSO), of 0.00244, 0.00488, 0.0097656, 0.01953125 and 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation. Strain-specific positive control substances were also included in the test: Sodium azide (TA100, TA1535: 0.5 µg/plate, without S9 mix, 2-Nitrofluorene (TA 98: 10 µg/plate, without S9 mix), 9-Aminoacridine (TA1537: 50 µg/plate without S9 mix), Mitomycin-C (TA102: 0.4 µg/plate, without S9 mix), Benzo[a] pyrene (TA98, TA100, TA1535, TA1537: 10 µg/plate with S9 mix). Results: Trial I was performed according to the plate incorporation method in Salmonella typhimurium TA98, TA100, TA102, TA1535, and TA1537 strains using five concentrations of the test substance, negative, vehicle and positive controls both in the presence (10 % v/v S9 mix) and absence of metabolic activation. Cytotoxicity, demonstrated as moderate inhibition in the background lawn growth and a slight reduction in the revertant count, was observed at the concentration of 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation when compared to the vehicle control data. No reduction in the revertant count was observed at the concentrations from 0.01953125 to 0.00244 mg/plate, neither in the presence (10% v/v S9 mix) nor the absence of metabolic activation when compared to the vehicle control data. Furthermore, no trend of an increased number of revertant colonies with increased dosing of the Test Item was observed. Trial II was conducted according to the preincubation method to confirm the negative results observed in Trial I. Trial II was performed in Salmonella typhimurium tester strains TA98, TA100, TA102, TA1535, and TA1537 employing test substance concentrations of 0.00244, 0.00488, 0.0097656, 0.01953125 and 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation system with all the tester strains along with the negative, vehicle and positive controls. A moderate inhibition in the background lawn and a slight reduction in the revertant count (cytotoxicity) was observed at the concentration of 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation compared to the vehicle control. No increase in the number of revertant colonies was observed up to the highest concentration of 0.0390625 mg/plate either in the presence (10 % v/v S9 mix) or absence of metabolic activation when compared to the vehicle control data. Furthermore, no trend of an increased number of revertant colonies with increased dosing of the test substance was observed. The dose concentration of the Test Item in dose formulation was analysed by a validated test method for all concentrations, and the observed concentration was within the acceptable limit of linearity (R) ≥0.99, % recovery 70-110 % and % RSD ≤ 10%. For each tester strain, the frequency of the spontaneous revertant colonies in the vehicle control was within the acceptable range of historical data of the lab. The positive controls used in the study produced significant increases in the mean number of revertant colonies in all of the tester strains compared to the control, thus confirming the validity of the test system to detect specific mutagens in the presence and absence of a metabolic activation system. Conclusion: The registered substance of 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1) did not induce gene mutation in the histidine operon of Salmonella Typhimurium tester strains (TA98, TA100, TA1535, TA1537 and TA102) either in the presence (10 % v/v S9 mix) or absence of S9 metabolic activation system when was tested up to a cytotoxic concentration.
Referenceopen allclose all
Appendix 1: Relative Survival – Preliminary Cytotoxicity Assay-I:Absence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23400000 | - | - | - | - | - | - | - | - |
VC | Dimethyl sulfoxide | 20000000 | 23200000 | - | - | - | - | - | - | - | - |
T1 | 0.125 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T2 | 0.25 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T3 | 0.5 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T4 | 1 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T5 | 2 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
Appendix 2: Relative Survival – Preliminary Cytotoxicity Assay-I: Presence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23600000 | - | - | - | - | - | - | - | - |
VC | Distilled water | 20000000 | 23400000 | - | - | - | - | - | - | - | - |
T1 | 0.125 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T2 | 0.25 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T3 | 0.5 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T4 | 1 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T5 | 2 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
Appendix 3: Preliminary Cytotoxicity Assay-II: Absence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23700000 | 231 | 235 | 230 | 232.00 | 100 | 2.320 | 2.749 | 100.00 |
VC | Dimethyl sulfoxide | 20000000 | 23500000 | 236 | 228 | 229 | 231.00 | 100 | 2.310 | 2.714 | 98.73 |
T1 | 0.00625 mg/ml | 20000000 | 18800000 | 52 | 55 | 51 | 52.67 | 100 | 0.527 | 0.495 | 18.24 |
T2 | 0.0125 mg/ml | 20000000 | 6800000 | 4 | 10 | 5 | 6.33 | 100 | 0.063 | 0.022 | 0.79 |
T3 | 0.025 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T4 | 0.05 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T5 | 0.1 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
Appendix 4: Relative Survival – Preliminary Cytotoxicity Assay -II: Presence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23600000 | 233 | 230 | 226 | 229.67 | 100 | 2.297 | 2.710 | 100.00 |
VC | Dimethyl sulfoxide | 20000000 | 23400000 | 218 | 216 | 220 | 218.00 | 100 | 2.180 | 2.551 | 94.12 |
T1 | 0.00625 mg/ml | 20000000 | 16800000 | 46 | 48 | 54 | 49.33 | 100 | 0.493 | 0.414 | 16.25 |
T2 | 0.0125 mg/ml | 20000000 | 5400000 | 8 | 3 | 4 | 5.00 | 100 | 0.050 | 0.014 | 0.53 |
T3 | 0.025 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T4 | 0.05 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
T5 | 0.1 mg/ml | 20000000 | 0 | - | - | - | - | - | - | - | - |
Appendix 5: Relative Survival – Main Study: Absence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23600000 | 230 | 236 | 231 | 232.33 | 100 | 2.323 | 2.742 | 100.00 |
VC | Dimethyl sulfoxide | 20000000 | 23400000 | 228 | 218 | 225 | 223.67 | 100 | 2.237 | 2.617 | 95.45 |
T1 | 0.78 µg/ml | 20000000 | 22800000 | 179 | 182 | 186 | 182.33 | 100 | 1.823 | 2.079 | 79.43 |
T2 | 1.56 µg/ml | 20000000 | 21800000 | 158 | 168 | 155 | 160.33 | 100 | 1.603 | 1.748 | 66.78 |
T3 | 3.13 µg/ml | 20000000 | 19800000 | 115 | 126 | 128 | 123.00 | 100 | 1.230 | 1.218 | 46.53 |
T4 | 6.25 µg/ml | 20000000 | 18400000 | 58 | 50 | 52 | 53.33 | 100 | 0.533 | 0.491 | 18.75 |
PC | 400 µg/ml | 20000000 | 18600000 | 198 | 226 | 219 | 214.33 | 100 | 2.143 | 1.993 | 76.17 |
Appendix 6:Relative Survival – Main Study: Presence of metabolic activation
Dose level | Concentration | No. of Cells | No. of colonies | Mean Colony count | No. of cells seeded | CE | Adjusted CE | RS | |||
Before | After | R1 | R2 | R3 | |||||||
NC | Distilled water | 20000000 | 23500000 | 226 | 235 | 232 | 231.00 | 100 | 2.310 | 2.714 | 100.00 |
VC | Dimethyl sulfoxide | 20000000 | 23300000 | 220 | 226 | 231 | 225.67 | 100 | 2.257 | 2.629 | 96.86 |
T1 | 0.78 µg/ml | 20000000 | 22600000 | 186 | 191 | 194 | 190.33 | 100 | 1.903 | 2.151 | 81.81 |
T2 | 1.56 µg/ml | 20000000 | 21600000 | 160 | 171 | 166 | 165.67 | 100 | 1.657 | 1.789 | 68.06 |
T3 | 3.13 µg/ml | 20000000 | 19800000 | 128 | 120 | 124 | 124.00 | 100 | 1.240 | 1.228 | 46.69 |
T4 | 6.25 µg/ml | 20000000 | 16300000 | 60 | 54 | 59 | 57.67 | 100 | 0.577 | 0.470 | 17.88 |
PC | 30 µg/ml | 20000000 | 18800000 | 218 | 214 | 225 | 219.00 | 100 | 2.190 | 2.059 | 78.30 |
Appendix 7: Cloning Efficiency (Non-selective medium) Main Study: Absence of metabolic activation
Dose level | Non Selective medium | ||||||
Concentration | No. of cells seeded | No. of colonies | Mean No. of colonies | CE | |||
R1 | R2 | R3 | |||||
NC | Distilled water | 100 | 219 | 226 | 224 | 223 | 2.23 |
VC | Dimethyl sulfoxide | 100 | 210 | 216 | 211 | 212 | 2.12 |
T1 | 0.78 µg/ml | 100 | 195 | 190 | 190 | 192 | 1.92 |
T2 | 1.56 µg/ml | 100 | 186 | 171 | 177 | 178 | 1.78 |
T3 | 3.13 µg/ml | 100 | 158 | 166 | 169 | 164 | 1.64 |
T4 | 6.25 µg/ml | 100 | 128 | 139 | 133 | 133 | 1.33 |
PC | 400 µg/ml | 100 | 192 | 190 | 186 | 189 | 1.89 |
Appendix 8:Cloning Efficiency (Non-selective medium) Main Study: Presence of metabolic activation
Dose level | Non Selective medium | ||||||
Concentration | No. of cells seeded | No. of colonies | Mean No. of colonies | CE | |||
R1 | R2 | R3 | |||||
NC | Distilled water | 100 | 224 | 218 | 224 | 222 | 2.22 |
VC | Dimethyl sulfoxide | 100 | 220 | 218 | 216 | 218 | 2.18 |
T1 | 0.78 µg/ml | 100 | 193 | 191 | 186 | 190 | 1.90 |
T2 | 1.56 µg/ml | 100 | 178 | 177 | 170 | 175 | 1.75 |
T3 | 3.13 µg/ml | 100 | 160 | 166 | 164 | 163 | 1.63 |
T4 | 6.25 µg/ml | 100 | 128 | 130 | 121 | 126 | 1.26 |
PC | 30 µg/ml | 100 | 183 | 190 | 182 | 185 | 1.85 |
Appendix 9: Cloning Efficiency (Selective medium): Absence of metabolic activation
Dose level | Selective medium | ||||||
Concentration | No. of cells seeded | No. of colonies | Mean No. of colonies | CE | |||
R1 | R2 | R3 | |||||
NC | Distilled water | 200000 | 2 | 3 | 3 | 2.67 | 0.00001333 |
VC | Dimethyl sulfoxide | 200000 | 4 | 2 | 3 | 3.00 | 0.00001500 |
T1 | 0.78 µg/ml | 200000 | 4 | 4 | 3 | 3.67 | 0.00001833 |
T2 | 1.56 µg/ml | 200000 | 3 | 2 | 5 | 3.33 | 0.00001667 |
T3 | 3.13 µg/ml | 200000 | 4 | 4 | 5 | 4.33 | 0.00002167 |
T4 | 6.25 µg/ml | 200000 | 2 | 4 | 4 | 3.33 | 0.00001667 |
PC | 400 µg/ml | 200000 | 90 | 89 | 84 | 87.67 | 0.00043833 |
Appendix 10: Cloning Efficiency (Selective medium) Phase I: Presence of metabolic activation
Dose level | Selective medium |
| |||||
Concentration | No. of cells seeded | No. of colonies | Mean No. of colonies | CE | |||
R1 | R2 | R3 | |||||
NC | Distilled water | 200000 | 4 | 2 | 2 | 2.67 | 0.00001333 |
VC | Dimethyl sulfoxide | 200000 | 3 | 5 | 3 | 3.67 | 0.00001833 |
T1 | 0.78 µg/ml | 200000 | 2 | 4 | 4 | 3.33 | 0.00001667 |
T2 | 1.56 µg/ml | 200000 | 5 | 3 | 3 | 3.67 | 0.00001833 |
T3 | 3.13 µg/ml | 200000 | 4 | 3 | 3 | 3.33 | 0.00001667 |
T4 | 6.25 µg/ml | 200000 | 4 | 2 | 4 | 3.33 | 0.00001667 |
PC | 30 µg/ml | 200000 | 79 | 88 | 84 | 83.67 | 0.00041833 |
Appendix 11: Mutation Frequency: Absence of metabolic activation
Dose level | Absence of metabolic activation | ||
Concentration | Mutation Frequency | MF x 10-6 | |
NC | Distilled water | 0.00000598 | 5.98 |
VC | Dimethyl sulfoxide | 0.00000706 | 7.06 |
T1 | 0.78 µg/ml | 0.00000957 | 9.57 |
T2 | 1.56 µg/ml | 0.00000936 | 9.36 |
T3 | 3.13 µg/ml | 0.00001318 | 13.18 |
T4 | 6.25 µg/ml | 0.00001250 | 12.50 |
PC | 400 µg/ml* | 0.00023151 | 231.51 |
Dose level | Presence of metabolic activation | ||
Concentration | Mutation Frequency | MF x 10-6 | |
NC | Distilled water | 0.00000601 | 6.01 |
VC | Dimethyl sulfoxide | 0.00000841 | 8.41 |
T1 | 0.78 µg/ml | 0.00000877 | 8.77 |
T2 | 1.56 µg/ml | 0.00001048 | 10.48 |
T3 | 3.13 µg/ml | 0.00001020 | 10.20 |
T4 | 6.25 µg/ml | 0.00001319 | 13.19 |
PC | 30 µg/ml* | 0.00022613 | 226.13 |
Key: NC = Negative Control, VC = Vehicle Control, PC = Positive Control (Absence of metabolic activation- Ethylmethanesulfonate, Presence of metabolic activation- Benzo[a]pyrene), T4-T1= Test item concentration from higher to lower, MF = Mutation Frequency, µg =microgram, ml = millilitre, * = Statistically significant increase in mutation frequency.
Annexure 1: Historical control data
Mutation Frequency (10-6) | NC | VC | PC |
| ||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 |
| ||
Mean | 7.45 | 7.33 | 7.78 | 7.92 | 229.63 | 236.21 |
| |
SD | 0.84 | 0.98 | 0.86 | 0.52 | 20.72 | 17.21 |
| |
Min | 6.09 | 6.02 | 6.35 | 6.51 | 197.57 | 209.32 |
| |
Max | 8.51 | 8.8 | 8.9 | 8.7 | 269 | 268.63 |
| |
|
|
Key: - NC = Negative Control (Distilled water), VC = Vehicle Control (Dimethyl sulfoxide), PC = Positive Control (Absence of metabolic activation- Ethylmethanesulfonate, Presence of metabolic activation- Benzo[a]pyrene), SD = Standard Deviation, Min = Minimum, Max = Maximum, - S9 = Absence of metabolic activation, +S9 = Presence of metabolic activation. Number of studies = 12.
Appendix1: RelativeIncrease in Cell Counts – Preliminary Cytotoxicity Assay
Dose Level | Conc. (mg/ml) | Absence of Metabolic activation | Presence of Metabolic activation | ||||||
Cell count | RICC | % Cytotoxicity | Cell count | RICC | % Cytotoxicity | ||||
Starting | Final | Starting | Final | ||||||
NC | Distilled water | 1000000 | 3580000 | 100.00 | 0.00 | 1000000 | 3584000 | 100.00 | 0.00 |
VC | DMSO | 1000000 | 3560000 | 99.22 | 0.78 | 1000000 | 3470000 | 95.59 | 4.41 |
T1 | 0.125 | 1000000 | 0 | 0.00 | 100.00 | 1000000 | 0 | 0.00 | 100.00 |
T2 | 0.25 | 1000000 | 0 | 0.00 | 100.00 | 1000000 | 0 | 0.00 | 100.00 |
T3 | 0.5 | 1000000 | 0 | 0.00 | 100.00 | 1000000 | 0 | 0.00 | 100.00 |
T4 | 1 | 1000000 | 0 | 0.00 | 100.00 | 1000000 | 0 | 0.00 | 100.00 |
T5 | 2 | 1000000 | 0 | 0.00 | 100.00 | 1000000 | 0 | 0.00 | 100.00 |
Key: NC = Negative Control, VC = Vehicle Control, Conc. = Concentration, mg = milligram, ml = milliliter, RICC = Relative Increase in Cell Counts, % = percentage.
Appendix3: Relative Increase in Cell Counts- Main Study
Dose Level | Conc.
| Phase I -Absence of Metabolic activation | |||
Cell count | RICC | % Cytotoxicity | |||
Starting | Final | ||||
NC | Distilled water | 1000000 | 3586000 | 100.00 | 0.00 |
VC | DMSO | 1000000 | 3530000 | 97.83 | 2.17 |
T1 | 0.0015625 mg/ml | 1000000 | 2742000 | 68.85 | 31.15 |
T2 | 0.003125 mg/ml | 1000000 | 2342000 | 53.04 | 46.96 |
T3 | 0.00625 mg/ml | 1000000 | 2160000 | 45.85 | 54.15 |
PC | 20 µg/ml | 1000000 | 2842000 | 72.81 | 27.19 |
Dose Level | Conc. | Phase II -Presence of Metabolic activation | |||
Cell count | RICC | % Cytotoxicity | |||
Starting | Final | ||||
NC | Distilled water | 1000000 | 3550000 | 100.00 | 0.00 |
VC | DMSO | 1000000 | 3460000 | 96.47 | 3.53 |
T1 | 0.0015625 mg/ml | 1000000 | 2644000 | 66.83 | 33.17 |
T2 | 0.003125 mg/ml | 1000000 | 2386000 | 56.34 | 43.66 |
T3 | 0.00625 mg/ml | 1000000 | 2018000 | 41.38 | 58.62 |
PC | 30 µg/ml | 1000000 | 2642000 | 66.75 | 33.25 |
Dose Level | Conc. | Phase III -Absence of Metabolic activation | |||
Cell count | RICC | % Cytotoxicity | |||
Starting | Final | ||||
NC | Distilled water | 1000000 | 3582000 | 100.00 | 0.00 |
VC | DMSO | 1000000 | 3460000 | 95.27 | 4.73 |
T1 | 0.0015625 mg/ml | 1000000 | 2582000 | 64.31 | 35.69 |
T2 | 0.003125 mg/ml | 1000000 | 2282000 | 52.11 | 47.89 |
T3 | 0.00625 mg/ml | 1000000 | 2024000 | 41.63 | 58.37 |
PC | 20 µg/ml | 1000000 | 2682000 | 68.37 | 31.63 |
Key: NC = Negative Control, VC = Vehicle Control, PC = Positive Control, Conc. = Concentration, mg = milligram, ml = milliliter, µg = microgram, RICC = Relative Increase in Cell Counts, % = percentage.
Appendix7: Summary Dataon Chromosome Aberrations - Phase I
Dose Level | Concentration
| Absence of metabolic activation | |
Total No. of Aberrant cells without gap | Percent aberrant cells | ||
NC | Distilled water | 0 | 0.00 |
VC | DMSO | 0 | 0.00 |
T1 | 0.0015625 mg/ml | 2 | 0.67 |
T2 | 0.003125 mg/ml | 1 | 0.33 |
T3 | 0.00625 mg/ml | 1 | 0.33 |
PC | 20 µg/ml* | 24 | 8.00 |
Key: NC = Negative Control (distilled water), VC = Vehicle Control (dimethyl sulfoxide), PC = Positive Control, mg = milligram, ml = milliliter, µg = microgram,* = Statistical significant increase in % aberrant cell (p<0.05).
Appendix8:Summary Data on Chromosome Aberrations - Phase II
Dose Level | Concentration
| Presence of metabolic activation | |
Total No. of Aberrant cells without gap | Percent aberrant cells | ||
NC | Distilled water | 0 | 0.00 |
VC | DMSO | 0 | 0.00 |
T1 | 0.0015625 mg/ml | 2 | 0.67 |
T2 | 0.003125 mg/ml | 0 | 0.00 |
T3 | 0.00625 mg/ml | 2 | 0.67 |
PC | 30 µg/ml* | 21 | 7.00 |
Key: NC = Negative Control (distilled water), VC = Vehicle Control (dimethyl sulfoxide), PC = Positive Control, mg = milligram, ml = milliliter, µg = microgram,* = Statistical significant increase in % aberrant cell (p<0.05).
Appendix 9: SummaryData on Chromosome Aberrations - Phase III
Dose Level | Concentration | Absence of metabolic activation | |
Total No. of Aberrant cells without gap | Percent aberrant cells | ||
NC | Distilled water | 0 | 0.00 |
VC | DMSO | 0 | 0.00 |
T1 | 0.0015625 mg/ml | 1 | 0.33 |
T2 | 0.003125 mg/ml | 1 | 0.33 |
T3 | 0.00625 mg/ml | 2 | 0.67 |
PC | 20 µg/ml* | 27 | 9.00 |
Key: NC = Negative Control (distilled water), VC = Vehicle Control (dimethyl sulfoxide), PC = Positive Control, mg = milligram, ml = milliliter, µg = microgram,* = Statistical significant increase in % aberrant cell (p<0.05).
Table 1: Mean Revertant Colony Count – Preliminary Cytotoxicity Assay
Test Item Concentration (mg/plate) | TA 98 | TA 100 | ||||||
- S9 | + S9 | - S9 | + S9 | |||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
NC (Distilled water) | 21 (NI) | 2.00 | 19 (NI) | 1.15 | 104 (NI) | 5.51 | 102 (NI) | 5.51 |
VC (Dimethyl sulfoxide) | 19 (NI) | 2.31 | 19 (NI) | 0.00 | 99 (NI) | 2.52 | 99 (NI) | 2.08 |
T1 (0.0390625) | 16 (MI) | 1.53 | 16 (MI) | 1.15 | 76 (MI) | 2.31 | 75 (MI) | 3.06 |
T2 (0.078125) | 11 (MI) | 2.08 | 8 (MI) | 1.15 | 30 (MI) | 3.21 | 23 (MI) | 1.15 |
T3 (0.15625) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
T4 (0.3125) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
T5 (0.625) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
T6 (1.25) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
T7 (2.5) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
T8 (5.0) | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 | 0 (CI) | 0.00 |
PC | 317 (NI) | 8.50 | 339 (NI) | 7.55 | 710 (NI) | 14.00 | 726 (NI) | 7.21 |
Key: NC = Negative control, VC = Vehicle control, PC = Positive Control, -S9 = Absence of metabolic activation, +S9 = Presence of metabolic activation, SD = Standard Deviation, T1-T8 = Test Item concentration from lower to higher, NI = No Inhibition, MI = Moderate inhibition, CI = Complete inhibition.
Positive Controls:
2-Nitrofluorene | : | TA98 (absence of metabolic activation) |
Sodium azide | : | TA100 (absence of metabolic activation) |
Benzo[a]pyrene | : | TA98 and TA100 (presence of metabolic activation) |
Table 2: Mean Revertant Colony Count in Trial I (Plate Incorporation Method)
Absence of metabolic activation | Presence of metabolic activation (+S9 10% v/v S9 Mix) | |||||||||||||||||||
Test Item Concentration (mg/plate) | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | ||||||||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
NC (Distilled water) | 20 | 2.89 | 93 | 6.43 | 13 | 1.15 | 7 | 1.15 | 230 | 6.66 | 19 | 0.58 | 98 | 4.36 | 14 | 2.65 | 6 | 0.58 | 224 | 7.81 |
VC (Dimethyl sulfoxide) | 18 | 0.58 | 93 | 2.52 | 13 | 0.58 | 7 | 1.53 | 236 | 9.00 | 20 | 2.89 | 94 | 2.00 | 14 | 0.58 | 6 | 1.73 | 225 | 6.43 |
T1 (0.00244) | 19 | 1.15 | 92 | 5.57 | 12 | 1.73 | 7 | 1.15 | 226 | 7.37 | 18 | 1.53 | 91 | 2.08 | 12 | 0.58 | 6 | 0.58 | 219 | 9.17 |
T2 (0.00488) | 20 | 3.06 | 92 | 2.65 | 13 | 1.73 | 6 | 1.15 | 218 | 8.19 | 20 | 1.73 | 93 | 2.00 | 14 | 2.31 | 6 | 1.15 | 225 | 6.24 |
T3 (0.0097656) | 20 | 2.89 | 88 | 2.08 | 14 | 0.58 | 7 | 1.15 | 210 | 4.93 | 20 | 2.89 | 86 | 3.51 | 13 | 0.58 | 6 | 0.00 | 218 | 8.08 |
T4 (0.01953125) | 17 | 1.15 | 86 | 3.61 | 12 | 1.15 | 6 | 1.53 | 206 | 9.29 | 17 | 0.00 | 83 | 3.06 | 11 | 0.58 | 4 | 0.58 | 214 | 4.93 |
T5 (0. 0390625) | 15 | 1.15 | 73 | 4.51 | 9 | 1.15 | 2 | 1.15 | 178 | 9.85 | 13 | 0.58 | 69 | 1.53 | 8 | 0.00 | 2 | 0.58 | 179 | 4.04 |
PC | 321 | 4.16 | 673 | 14.84 | 317 | 10.02 | 188 | 6.24 | 1643 | 39.50 | 317 | 9.54 | 690 | 15.95 | 306 | 10.02 | 198 | 8.54 | 1627 | 7.51 |
Key: NC = Negative control, VC = Vehicle control, PC = Positive Control, -S9 = Absence of metabolic activation, +S9 = Presence of metabolic activation, SD = Standard Deviation, T1-T5 = Test Item concentration from lower to higher.
Positive Controls:
2-Nitrofluorene | : | TA98 (absence of metabolic activation) |
Sodium azide | : | TA100 and TA1535 (absence of metabolic activation) |
9-Aminoacridine | : | TA1537 (absence of metabolic activation) |
Mitomycin-C | : | TA102 (absence of metabolic activation) |
Benzo[a]pyrene | : | TA98, TA100, TA1535, TA1537 and TA102 (presence of metabolic activation) |
Table 3: Mean Revertant Colony Count in Trial II (Preincubation Method)
Absence of metabolic activation | Presence of metabolic activation (+S9 10% v/v S9 Mix) | |||||||||||||||||||
Test Item Concentration (mg/plate) | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | ||||||||||
Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
NC (Distilled water) | 21 | 2.5 | 94 | 3.46 | 14 | 1.15 | 6 | 0.58 | 232 | 5.51 | 19 | 0.58 | 98 | 5.51 | 14 | 2.00 | 7 | 1.15 | 228 | 2.08 |
VC (Dimethyl sulfoxide) | 19 | 1.2 | 92 | 3.06 | 13 | 1.73 | 6 | 1.15 | 224 | 5.13 | 20 | 1.73 | 93 | 6.66 | 13 | 1.73 | 6 | 1.00 | 229 | 7.00 |
T1 (0.00244) | 18 | 0.6 | 92 | 2.31 | 12 | 0.58 | 7 | 1.15 | 222 | 6.66 | 21 | 2.31 | 91 | 1.53 | 12 | 1.73 | 7 | 1.15 | 219 | 9.29 |
T2 (0.00488) | 19 | 1.5 | 95 | 2.31 | 14 | 1.73 | 6 | 1.15 | 230 | 6.24 | 17 | 0.58 | 93 | 2.08 | 13 | 1.73 | 7 | 0.58 | 211 | 3.51 |
T3 (0.0097656) | 19 | 0.6 | 91 | 2.08 | 15 | 2.31 | 7 | 1.15 | 227 | 9.00 | 23 | 2.31 | 90 | 0.58 | 13 | 1.15 | 6 | 1.73 | 220 | 4.58 |
T4 (0.01953125) | 17 | 0.6 | 88 | 6.81 | 11 | 1.53 | 4 | 0.58 | 207 | 11.02 | 17 | 0.58 | 89 | 2.89 | 12 | 1.73 | 5 | 0.58 | 204 | 6.93 |
T5 (0. 0390625) | 14 | 0.6 | 67 | 3.21 | 8 | 0.58 | 2 | 2.23 | 173 | 6.51 | 13 | 2.08 | 65 | 3.21 | 7 | 1.15 | 2 | 1.73 | 160 | 3.00 |
PC | 324 | 4.4 | 724 | 7.77 | 333 | 8.14 | 215 | 8.02 | 1710 | 13.01 | 320 | 9.50 | 721 | 0.58 | 334 | 7.57 | 218 | 10.41 | 1721 | 30.75 |
Table 4: Fold Increase
Trial I - Plate Incorporation Method | Trial II – Preincubation Method | |||||||||||||||||||
Test Item Concentration (mg/plate) | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | TA 98 | TA 100 | TA 1535 | TA 1537 | TA 102 | ||||||||||
-S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | |
NC (Distilled water) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
VC (Dimethyl sulfoxide) | 0.90 | 1.02 | 0.99 | 0.96 | 0.95 | 0.98 | 0.91 | 0.95 | 1.02 | 1.01 | 0.90 | 1.03 | 0.98 | 0.96 | 0.91 | 0.93 | 0.89 | 0.90 | 0.97 | 1.01 |
T1 (0.00244) | 1.09 | 0.93 | 0.99 | 0.96 | 0.95 | 0.90 | 1.00 | 1.06 | 0.96 | 0.97 | 0.95 | 1.03 | 1.00 | 0.98 | 0.95 | 0.92 | 1.18 | 1.11 | 0.99 | 0.96 |
T2 (0.00488) | 1.15 | 1.02 | 0.99 | 0.99 | 1.03 | 1.00 | 0.95 | 0.94 | 0.92 | 1.00 | 1.04 | 0.87 | 1.03 | 0.99 | 1.08 | 1.00 | 1.00 | 1.22 | 1.03 | 0.92 |
T3 (0.0097656) | 1.11 | 1.00 | 0.95 | 0.92 | 1.08 | 0.93 | 1.00 | 1.00 | 0.89 | 0.97 | 1.04 | 1.15 | 0.99 | 0.96 | 1.13 | 1.03 | 1.18 | 1.00 | 1.01 | 0.96 |
T4 (0.01953125) | 0.98 | 0.86 | 0.93 | 0.88 | 0.97 | 0.78 | 0.95 | 0.72 | 0.87 | 0.95 | 0.93 | 0.87 | 0.95 | 0.95 | 0.87 | 0.92 | 0.76 | 0.78 | 0.93 | 0.89 |
T5 (0. 0390625) | 0.83 | 0.68 | 0.79 | 0.73 | 0.68 | 0.59 | 0.35 | 0.39 | 0.75 | 0.80 | 0.73 | 0.63 | 0.72 | 0.70 | 0.59 | 0.56 | 0.29 | 0.33 | 0.77 | 0.70 |
PC | 18.19 | 16.12 | 7.27 | 7.34 | 25.00 | 22.37 | 28.20 | 33.00 | 6.96 | 7.22 | 17.36 | 16.02 | 7.84 | 7.73 | 25.64 | 25.67 | 38.00 | 36.39 | 7.65 | 7.52 |
Table 5: S9 Efficacy Check- Summary
Summary of S9 efficacy check | ||||
| TA100 | TA1535 | ||
Mean | SD | Mean | SD | |
VC Dimethyl sulfoxide (-S9) | 99 | 2.52 | 13 | 0.58 |
VC Dimethyl sulfoxide (+S9) | 99 | 2.08 | 14 | 0.58 |
PC Benzo[a]pyrene (-S9) | 100 | 3.06 | 15 | 2.31 |
PC Benzo[a]pyrene (+S9) | 726 | 7.21 | 306 | 10.02 |
Appendix 1: Individual Revertant Colony Count-Preliminary Cytotoxicity Assay
Test Item Concentration (mg/plate) | R | TA98 | TA100 | ||||||
-S9 | BL | +S9 | BL | -S9 | BL | +S9 | BL | ||
NC (Distilled water) | 1 | 23 | NI | 20 | NI | 98 | NI | 102 | NI |
2 | 21 | NI | 20 | NI | 109 | NI | 107 | NI | |
3 | 19 | NI | 18 | NI | 104 | NI | 96 | NI | |
VC (Dimethyl sulfoxide) | 1 | 18 | NI | 19 | NI | 96 | NI | 101 | NI |
2 | 18 | NI | 19 | NI | 101 | NI | 98 | NI | |
3 | 22 | NI | 19 | NI | 99 | NI | 97 | NI | |
T1 (0.0390625) | 1 | 17 | MI | 15 | MI | 79 | MI | 78 | MI |
2 | 16 | MI | 17 | MI | 75 | MI | 72 | MI | |
3 | 14 | MI | 17 | MI | 75 | MI | 76 | MI | |
T2 (0.078125) | 1 | 10 | MI | 9 | MI | 34 | MI | 24 | MI |
2 | 13 | MI | 7 | MI | 28 | MI | 22 | MI | |
3 | 9 | MI | 7 | MI | 29 | MI | 22 | MI | |
T3 (0.15625) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
T4 (0.3125) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
T5 (0.625) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
T6 (1.25) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
T7 (2.5) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
T8 (5.0) | 1 | 0 | CI | 0 | CI | 0 | CI | 0 | CI |
2 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
3 | 0 | CI | 0 | CI | 0 | CI | 0 | CI | |
PC | 1 | 309 | NI | 332 | NI | 716 | NI | 720 | NI |
2 | 317 | NI | 347 | NI | 694 | NI | 734 | NI | |
3 | 326 | NI | 338 | NI | 720 | NI | 724 | NI |
Appendix 2: Individual Revertant Colony Count-Trial I (Plate Incorporation Method)
Absence of Metabolic Activation | Presence of Metabolic Activation | |||||||||||
Test Item Concentration (mg/plate) | R | TA98 | TA100 | TA1535 | TA1537 | TA102 | R | TA98 | TA100 | TA1535 | TA1537 | TA102 |
NC (Distilled water) | 1 | 18 (NI) | 96 (NI) | 14 (NI) | 8 (NI) | 227 (NI) | 1 | 19 (NI) | 96 (NI) | 15 (NI) | 6 (NI) | 220 (NI) |
2 | 18 (NI) | 86 (NI) | 14 (NI) | 8 (NI) | 238 (NI) | 2 | 19 (NI) | 95 (NI) | 11 (NI) | 6 (NI) | 219 (NI) | |
3 | 23 (NI) | 98 (NI) | 12 (NI) | 6 (NI) | 226 (NI) | 3 | 20 (NI) | 103 (NI) | 16 (NI) | 7 (NI) | 233 (NI) | |
VC (Dimethyl sulfoxide) | 1 | 17 (NI) | 90 (NI) | 12 (NI) | 8 (NI) | 227 (NI) | 1 | 18 (NI) | 94 (NI) | 14 (NI) | 8 (NI) | 230 (NI) |
2 | 18 (NI) | 93 (NI) | 13 (NI) | 7 (NI) | 245 (NI) | 2 | 23 (NI) | 92 (NI) | 14 (NI) | 5 (NI) | 228 (NI) | |
3 | 18 (NI) | 95 (NI) | 13 (NI) | 5 (NI) | 236 (NI) | 3 | 18 (NI) | 96 (NI) | 13 (NI) | 5 (NI) | 218 (NI) | |
T1 (0.00244) | 1 | 20 (NI) | 86 (NI) | 11 (NI) | 6 (NI) | 218 (NI) | 1 | 17 (NI) | 90 (NI) | 12 (NI) | 6 (NI) | 217 (NI) |
2 | 20 (NI) | 93 (NI) | 11 (NI) | 8 (NI) | 229 (NI) | 2 | 18 (NI) | 89 (NI) | 12 (NI) | 6 (NI) | 211 (NI) | |
3 | 18 (NI) | 97 (NI) | 14 (NI) | 6 (NI) | 232 (NI) | 3 | 20 (NI) | 93 (NI) | 13 (NI) | 7 (NI) | 229 (NI) | |
T2 (0.00488) | 1 | 21 (NI) | 90 (NI) | 15 (NI) | 7 (NI) | 227 (NI) | 1 | 18 (NI) | 93 (NI) | 11 (NI) | 7 (NI) | 227 (NI) |
2 | 17 (NI) | 95 (NI) | 12 (NI) | 5 (NI) | 216 (NI) | 2 | 21 (NI) | 95 (NI) | 15 (NI) | 5 (NI) | 230 (NI) | |
3 | 23 (NI) | 91 (NI) | 12 (NI) | 7 (NI) | 211 (NI) | 3 | 21 (NI) | 91 (NI) | 15 (NI) | 5 (NI) | 218 (NI) | |
T3 (0.0097656) | 1 | 18 (NI) | 90 (NI) | 13 (NI) | 6 (NI) | 208 (NI) | 1 | 23 (NI) | 86 (NI) | 13 (NI) | 6 (NI) | 225 (NI) |
2 | 18 (NI) | 86 (NI) | 14 (NI) | 8 (NI) | 216 (NI) | 2 | 18 (NI) | 90 (NI) | 13 (NI) | 6 (NI) | 209 (NI) | |
3 | 23 (NI) | 89 (NI) | 14 (NI) | 6 (NI) | 207 (NI) | 3 | 18 (NI) | 83 (NI) | 12 (NI) | 6 (NI) | 219 (NI) | |
T4 (0.01953125) | 1 | 16 (NI) | 85 (NI) | 11 (NI) | 5 (NI) | 203 (NI) | 1 | 17 (NI) | 80 (NI) | 10 (NI) | 4 (NI) | 208 (NI) |
2 | 18 (NI) | 83 (NI) | 13 (NI) | 8 (NI) | 198 (NI) | 2 | 17 (NI) | 86 (NI) | 11 (NI) | 4 (NI) | 217 (NI) | |
3 | 18 (NI) | 90 (NI) | 13 (NI) | 6 (NI) | 216 (NI) | 3 | 17 (NI) | 82 (NI) | 11 (NI) | 5 (NI) | 216 (NI) | |
T5 (0. 0390625) | 1 | 14 (MI) | 69 (MI) | 10 (MI) | 3 (MI) | 186 (MI) | 1 | 13 (MI) | 70 (MI) | 8 (MI) | 2 (MI) | 180 (MI) |
2 | 14 (MI) | 78 (MI) | 8 (MI) | 3 (MI) | 181 (MI) | 2 | 14 (MI) | 67 (MI) | 8 (MI) | 3 (MI) | 175 (MI) | |
3 | 16 (MI) | 73 (MI) | 8 (MI) | 1 (MI) | 167 (MI) | 3 | 13 (MI) | 69 (MI) | 8 (MI) | 2 (MI) | 183 (MI) | |
PC | 1 | 320 (NI) | 686 (NI) | 327 (NI) | 186 (NI) | 1657(NI) | 1 | 308 (NI) | 708 (NI) | 305 (NI) | 197 (NI) | 1627(NI) |
2 | 318 (NI) | 657 (NI) | 307 (NI) | 195 (NI) | 1673(NI) | 2 | 316 (NI) | 686 (NI) | 296 (NI) | 207 (NI) | 1635(NI) | |
3 | 326 (NI) | 677 (NI) | 316 (NI) | 183 (NI) | 1598(NI) | 3 | 327 (NI) | 677 (NI) | 316 (NI) | 190 (NI) | 1620(NI) |
Appendix 3: Individual Revertant Colony Count-Trial II (Preincubation Method)
Absence of Metabolic Activation | Presence of Metabolic Activation | |||||||||||
Test Item Concentration (mg/plate) | R | TA98 | TA100 | TA1535 | TA1537 | TA102 | R | TA98 | TA100 | TA1535 | TA1537 | TA102 |
NC (Distilled water) | 1 | 18 (NI) | 96 (NI) | 13 (NI) | 6 (NI) | 226 (NI) | 1 | 19 (NI) | 98 (NI) | 16 (NI) | 6 (NI) | 230 (NI) |
2 | 23 (NI) | 96 (NI) | 15 (NI) | 6 (NI) | 237 (NI) | 2 | 20 (NI) | 103 (NI) | 12 (NI) | 8 (NI) | 226 (NI) | |
3 | 21 (NI) | 90 (NI) | 15 (NI) | 7 (NI) | 232 (NI) | 3 | 19 (NI) | 92 (NI) | 14 (NI) | 6 (NI) | 227 (NI) | |
VC (Dimethyl sulfoxide) | 1 | 20 (NI) | 93 (NI) | 14 (NI) | 7 (NI) | 225 (NI) | 1 | 18 (NI) | 91 (NI) | 15 (NI) | 6 (NI) | 224 (NI) |
2 | 18 (NI) | 89 (NI) | 11 (NI) | 5 (NI) | 218 (NI) | 2 | 21 (NI) | 94 (NI) | 12 (NI) | 7 (NI) | 237 (NI) | |
3 | 18 (NI) | 95 (NI) | 14 (NI) | 5 (NI) | 228 (NI) | 3 | 21 (NI) | 95 (NI) | 12 (NI) | 5 (NI) | 226 (NI) | |
T1 (0.00244) | 1 | 17 (NI) | 91 (NI) | 12 (NI) | 6 (NI) | 220 (NI) | 1 | 22 (NI) | 95 (NI) | 11 (NI) | 6 (NI) | 222 (NI) |
2 | 18 (NI) | 91 (NI) | 12 (NI) | 6 (NI) | 216 (NI) | 2 | 22 (NI) | 90 (NI) | 11 (NI) | 8 (NI) | 227 (NI) | |
3 | 18 (NI) | 95 (NI) | 13 (NI) | 8 (NI) | 229 (NI) | 3 | 18 (NI) | 89 (NI) | 14 (NI) | 6 (NI) | 209 (NI) | |
T2 (0.00488) | 1 | 19 (NI) | 92 (NI) | 15 (NI) | 7 (NI) | 232 (NI) | 1 | 18 (NI) | 90 (NI) | 15 (NI) | 7 (NI) | 208 (NI) |
2 | 21 (NI) | 96 (NI) | 12 (NI) | 5 (NI) | 223 (NI) | 2 | 17 (NI) | 95 (NI) | 12 (NI) | 8 (NI) | 215 (NI) | |
3 | 18 (NI) | 96 (NI) | 15 (NI) | 5 (NI) | 235 (NI) | 3 | 17 (NI) | 93 (NI) | 12 (NI) | 7 (NI) | 211 (NI) | |
T3 (0.0097656) | 1 | 19 (NI) | 89 (NI) | 16 (NI) | 6 (NI) | 218 (NI) | 1 | 19 (NI) | 86 (NI) | 14 (NI) | 5 (NI) | 216 (NI) |
2 | 19 (NI) | 93 (NI) | 16 (NI) | 6 (NI) | 227 (NI) | 2 | 19 (NI) | 93 (NI) | 14 (NI) | 8 (NI) | 219 (NI) | |
3 | 20 (NI) | 92 (NI) | 12 (NI) | 8 (NI) | 236 (NI) | 3 | 23 (NI) | 91 (NI) | 12 (NI) | 5 (NI) | 225 (NI) | |
T4 (0.01953125) | 1 | 17 (NI) | 90 (NI) | 11 (NI) | 5 (NI) | 218 (NI) | 1 | 18 (NI) | 86 (NI) | 13 (NI) | 5 (NI) | 208 (NI) |
2 | 17 (NI) | 80 (NI) | 13 (NI) | 4 (NI) | 208 (NI) | 2 | 17 (NI) | 90 (NI) | 10 (NI) | 4 (NI) | 196 (NI) | |
3 | 18 (NI) | 93 (NI) | 10 (NI) | 4 (NI) | 196 (NI) | 3 | 17 (NI) | 90 (NI) | 13 (NI) | 5 (NI) | 208 (NI) | |
T5 (0. 0390625) | 1 | 14 (MI) | 68 (MI) | 8 (MI) | 2 (MI) | 180 (MI) | 1 | 15 (MI) | 60 (MI) | 6 (MI) | 1 (MI) | 160 (MI) |
2 | 14 (MI) | 63 (MI) | 8 (MI) | 1 (MI) | 167 (MI) | 2 | 11 (MI) | 67 (MI) | 8 (MI) | 1 (MI) | 157 (MI) | |
3 | 13 (MI) | 69 (MI) | 7 (MI) | 2v | 173 (MI) | 3 | 12 (MI) | 68 (MI) | 8 (MI) | 4 (MI) | 163 (MI) | |
PC | 1 | 327 (NI) | 733 (NI) | 337 (NI) | 216 (NI) | 1711(NI) | 1 | 330 (NI) | 720 (NI) | 325 (NI) | 230 (NI) | 1736(NI) |
2 | 319 (NI) | 718 (NI) | 324 (NI) | 207 (NI) | 1697(NI) | 2 | 311 (NI) | 711 (NI) | 339 (NI) | 210 (NI) | 1742(NI) | |
3 | 326 (NI) | 722 (NI) | 339 (NI) | 223 (NI) | 1723(NI) | 3 | 320 (NI) | 733 (NI) | 337 (NI) | 215 (NI) | 1686(NI) |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Bacterial reverse mutation test (OECD 471):
The mutagenic potential of 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1) was tested according to OECD 471 in Salmonella Typhimurium TA98, TA100, TA1535, TA1537 and TA102 tester strains both in the presence and absence of an exogenous metabolic activation system. Cofactor-supplemented rat liver S9 microsomal fraction was applied as a metabolic activation system. The test substance was dissolved in dimethyl sulfoxide (DMSO). Slight precipitation was observed at a test substance concentration of 5 mg/plate, which was considered not to interfere with the scoring. Test concentrations were selected based on the solubility and precipitation checks and a preliminary cytotoxicity test. In this pre-test, the following concentrations were assessed using triplicate plates: 0.0 (NC), 0.0 (VC), 0.0390625, 0.078125, 0.15625, 0.3125, 0.625, 1.25, 2.5, and 5 mg/plate using tester strains TA98, and TA100. In tester strain TA98 and TA100, complete inhibition of background lawn was observed at ≥ 0.15625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to the vehicle control. Furthermore, a substantial reduction in the revertant count and moderate inhibition of the background lawn was observed at 0.078125 mg/plate, and a slight reduction in the number of revertant colonies accompanied by a moderate inhibition of the background lawn growth was observed at 0.0390625 mg/plate, both in the presence (10% v/v S9 mix) and absence of metabolic activation compared to vehicle control. Hence, in the mutagenicity test, the following concentrations were applied: 0.0 (NC, distilled water), 0.0 (VC, DMSO), of 0.00244, 0.00488, 0.0097656, 0.01953125 and 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation. Strain-specific positive control substances were also included in the test: Sodium azide (TA100, TA1535: 0.5 µg/plate, without S9 mix, 2-Nitrofluorene (TA 98: 10 µg/plate, without S9 mix), 9-Aminoacridine (TA1537: 50 µg/plate without S9 mix), Mitomycin-C (TA102: 0.4 µg/plate, without S9 mix), Benzo[a] pyrene (TA98, TA100, TA1535, TA1537: 10 µg/plate with S9 mix). Results: Trial I was performed according to the plate incorporation method in Salmonella typhimurium TA98, TA100, TA102, TA1535, and TA1537 strains using five concentrations of the test substance, negative, vehicle and positive controls both in the presence (10 % v/v S9 mix) and absence of metabolic activation. Cytotoxicity, demonstrated as moderate inhibition in the background lawn growth and a slight reduction in the revertant count, was observed at the concentration of 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation when compared to the vehicle control data. No reduction in the revertant count was observed at the concentrations from 0.01953125 to 0.00244 mg/plate, neither in the presence (10% v/v S9 mix) nor the absence of metabolic activation when compared to the vehicle control data. Furthermore, no trend of an increased number of revertant colonies with increased dosing of the Test Item was observed. Trial II was conducted according to the preincubation method to confirm the negative results observed in Trial I. Trial II was performed in Salmonella typhimurium tester strains TA98, TA100, TA102, TA1535, and TA1537 employing test substance concentrations of 0.00244, 0.00488, 0.0097656, 0.01953125 and 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation system with all the tester strains along with the negative, vehicle and positive controls. A moderate inhibition in the background lawn and a slight reduction in the revertant count (cytotoxicity) was observed at the concentration of 0.0390625 mg/plate both in the presence (10 % v/v S9 mix) and absence of metabolic activation compared to the vehicle control. No increase in the number of revertant colonies was observed up to the highest concentration of 0.0390625 mg/plate either in the presence (10 % v/v S9 mix) or absence of metabolic activation when compared to the vehicle control data. Furthermore, no trend of an increased number of revertant colonies with increased dosing of the test substance was observed. The dose concentration of the Test Item in dose formulation was analysed by a validated test method for all concentrations, and the observed concentration was within the acceptable limit of linearity (R) ≥0.99, % recovery 70-110 % and % RSD ≤ 10%. For each tester strain, the frequency of the spontaneous revertant colonies in the vehicle control was within the acceptable range of historical data of the lab. The positive controls used in the study produced significant increases in the mean number of revertant colonies in all of the tester strains compared to the control, thus confirming the validity of the test system to detect specific mutagens in the presence and absence of a metabolic activation system. Conclusion: The registered substance of 4,4’-bis(dimethylamino)-4”-(methylamino) trityl alcohol (CAS 561-41-1) did not induce gene mutation in the histidine operon of Salmonella Typhimurium tester strains (TA98, TA100, TA1535, TA1537 and TA102) either in the presence (10 % v/v S9 mix) or absence of S9 metabolic activation system when was tested up to a cytotoxic concentration.
In vitro mammalian chromosome aberration test (OECD 473):
This in vitro experiment was performed to evaluate the ability of4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1] to cause structural chromosomal aberrations in cultured CHO cells in the presence and absence of an exogenous metabolic activation system (S9). The study was performed as per OECD Test Guidelines No.473 (Adopted: 29 July 2016). Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system.The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat. The substance was soluble in dimethyl sulfoxide (DMSO); therefore, DMSO was used as a vehicle of the test substance during the test. Test concentrations were selected based on preliminary cytotoxicity tests I-II. In the preliminary cytotoxicity test I, CHO cells were exposed to 0.0 (NC), 0.0 (VC), 0.125, 0.25, 0.5, 1 and 2 mg/ml of the test substance both in the presence and absence of S9 metabolic activation (1 % v/v S9 mix). Excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.125 mg/ml, with and without S9 metabolic activation. In the preliminary cytotoxicity assay-II, CHO cells were treated with 0.0 (NC), 0.0 (VC), 0.0625, 0.0125, 0.025, 0.05 and 0.1 mg/ml of culture medium, both in the presence (1 % v/v S9 mix) and absence of metabolic activation system. In this second cytotoxicity assay, excessive cytotoxicity (defined by a Relative Increase in Cell Count [RICC] of <40% of the concurrent vehicle control data) was observed for the Test Item concentrations at ≥0.0125 mg/ml, both in the presence and absence of metabolic activation. At 0.00625 mg/ml, RICC decreased to 55±5% compared to vehicle control both in the presence and absence of metabolic activation; RICC were 46.86% (cytotoxicity: 53.14% and 42,69% (cytotoxicity: 57.31%) in the absence and presence of S9 metabolic activation system, respectively. Based on the cytotoxicity assay results, Phase I (short-term exposure in the absence of metabolic activation), Phase II (short-term exposure in the presence of metabolic activation) and Phase III (continuous exposure in the absence of metabolic activation) were conducted with the Test Item at the concentrations of 0.0015625, 0.003125 and 0.00625 mg/ml, along with vehicle (DMSO), negative (Distilled water) and concurrent positive controls (Methyl methanesulfonate: 20 µg/ml, without S9 mix; Benzo (a) pyrene: 30 µg/ml with S9 mix). Results: In Phase I, cultures were exposed to test substance, vehicle, and negative and positive control for 4 hours (short-term exposure) in the absence of metabolic activation. Average RICC values were 97.83 % (vehicle control), 68.85 % (at 0.0015625 mg/ml), 53.04 % (at 0.003125 mg/ml) and 45.85 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), 0.003125 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), 0.00625 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In Phase II, CHO cells were exposed to the test substance, vehicle, and negative and positive control for 4 hours (short-term exposure) in the presence of metabolic activation (1 % v/v S9 mix). Average RICC values were 96.47 % (vehicle control), 66.83 % (at 0.0015625 mg/ml), 56.34 % (at 0.003125 mg/ml) and 41.38 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), 0.003125 mg/ml (the mean % aberrant cells: 0.00%, p=1.0000), 0.00625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In Phase III, cultures were exposed to the substance, vehicle, negative and positive control for 24 hours (continuous exposure) in the absence of metabolic activation. Average RICC values were 95.27 % (vehicle control), 64.31 % (at 0.0015625 mg/ml), 52.11 % (at 0.003125 mg/ml) and 41.63 % (at 0.00625 mg/ml). No significant increase in the mean percent aberrant cells at 0.0015625 mg/ml (the mean % aberrant cells: 0.33%, p=1.000), 0.003125 mg/ml (the mean % aberrant cells: 0.33%, p=1.0000), 0.00625 mg/ml (the mean % aberrant cells: 0.67%, p=0.4992), was observed when compared to the vehicle control (the mean % aberrant cells 0.00 %). In all phases of the study, no significant reduction in RICC (cytotoxicity) and no increase in percent aberrant cells were observed in vehicle control (DMSO) either in the presence or absence of metabolic activation when compared to the negative control (distilled water). Conclusion: Based on the results of this study, it is concluded that 4,4’bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1]does not induce chromosomal aberration up to 0.00625 mg/ml of culture medium, either in the presence or absence of S9 metabolic activation system in CHO cells under the experimental conditions described.
In vitro gene mutation test (OECD 476):
The potential of 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol [CAS No.: 561-41-1], to induce gene mutation at the hypoxanthine-guanine phosphoribosyltransferase (Hprt) locus in cultured Chinese Hamster Ovary (CHO) cells was tested in the presence and absence of an exogenous metabolic activation system. The study was performed as per OECD Test Guideline No. 476 (Adopted: July 29 2016). Cofactor-supplemented liver S9 microsomal fraction was used as an exogenous metabolic activation system. The S9 microsomal (S9 homogenate) fraction derived from the liver of a phenobarbitone and β-naphthoflavone-injected rat. The test substance was soluble in dimethyl sulfoxide (DMSO) at 200 mg/ml; therefore, DMSO was selected as the vehicle of the substance in this assay. The test concentrations were selected based on preliminary cytotoxicity tests I-II. In the initial cytotoxicity test I, CHO cells were exposed to 0.0 (Distilled water), 0.0 (DMSO), 0.125, 0.25, 0.5, 1 and 2 mg/ml of test substance in the culture medium, both in the presence and absence of S9 metabolic activation system (1 % v/v S9 mix). After the 4-hour treatment, complete toxicity was observed at all the tested concentrations in the absence and presence of metabolic activation; therefore, an additional cytotoxicity assay was performed. The preliminary cytotoxicity test-II was performed with the following test concentrations: 0.0 (NC), 0.0 (VC), 0.00625, 0.0125, 0.025, 0.05 and 0.1 mg/ml in the culture medium, both in the presence and absence of metabolic activation system (1 % v/v S9 mix). Complete cytotoxicity was observed within the concentration range of 0.0125 - 2 mg/ml, both in the absence and presence of metabolic activation. Moderate cytotoxicity (>16% Relative Survival [RS is cloning efficiency (CE) of cells plated immediately after treatment adjusted by any loss of cells during treatment as compared with cloning efficiency in vehicle control]) was noted at 0.00625 mg/ml either in the absence (RS: 18.24%) or presence (RS: 16.25%) of metabolic activation. Hence, the gene mutation study was conducted with Test Item concentrations of 0.78, 1.56, 3.13 and 6.25 µg/ml, both in the presence (1 % v/v S9 mix) and absence of metabolic activation system along with negative (distilled water), vehicle (DMSO) and positive controls (Ethylmethanesulfonate: 400 µg/ml in the absence of S9 metabolic activation, Benzo (a) pyrene: 30 µg/ml in the presence of S9 metabolic activation). Results: In the main study, cultures were exposed to the negative control, vehicle control, different concentrations of the Test Item, and positive control for 4 hours (short-term exposure) in the absence and presence of metabolic activation. In the absence of metabolic activation, the Relative Survival values were 100% (negative control), 95.45% (vehicle control), 79.43% (at 0.78 µg/ml), 66.78% (at 1.56 µg/ml), 46.53% (at 3.13 µg/ml), 18.75% (at 6.25 µg/ml) and 76.17% (at 400 µg/ml-positive control [Ehtylmethanesulfonate]). In the presence of metabolic activation, the relative survival values were 100% (negative control), 96.86% (vehicle control), 81.81% (at 0.78 µg/ml), 68.06% (at 1.56 µg/ml), 46.69% (at 3.13 µg/ml) 17.88% (at 6.25 µg/ml) and 78.30% (30 µg/ml-positive control[Benzo[a]pyrene]). No significant increase in the mutation frequency (MF) either in the absence (9.57 x 10-6, 9.36 x 10-6, 13.18 x 10-6 and 12.50 x 10-6 at 0.78 µg/ml, 1.56 µg/ml, 3.13 µg/ml and 6.25 µg/ml, respectively) or presence of metabolic activation (8.77 x 10-6, 10.4 8 x 10-6, 10.20 x10-6 and 13.19 x10-6 at 0.78 µg/ml, 1.56 µg/ml, 3.13 µg/ml and 6.25 µg/ml, respectively) was observed when compared to vehicle control (5.98 x10-6, 6.01 x10-6, absence and presence of S9, respectively). The dose concentrations of the Test Item in dose formulation were analysed by a validated test method for all concentrations, and the observed concentrations were within the acceptable limit of linearity (R) ≥0.99, % recovery 70-110% and % RSD ≤ 10%. The positive controls (Ethylmethanesulfonate and Beno[a]pyrene in the absence and presence of metabolic activation, respectively) used in the study produced statistically significant increases in mutation frequency (231.51 x10-6, p<0.0001 [Ethylmethanesulfonate], 226.13 x10-6, p<0.0001 [Benzo(a)pyrene] in the absence and presence of metabolic activation, respectively) indicating the sensitivity of the test system to specific mutagens, and confirmed that the test conditions were appropriate and that the metabolic activation system functioned properly. Conclusion: The registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol (CAS No.: 561-41-1), did not induce a statistically significant or biologically relevant increase in the mutation frequency up to 6.26 µg/ml when compared to the vehicle control either in the presence or in the absence of S9 metabolic activation.
Justification for classification or non-classification
The registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol (CAS 561-41-1), has been tested non-mutagenic (negative) in five Salmonella Typhimurium tester strains according to OECD TG 471. The substance has been tested non-clastogenic (negative ) in cultured Chinese Hamster Ovary cells in the presence or absence of an exogenous metabolic activation system in an in vitro cytogenicity test performed according to OECD TG 473. In addition, the registered substance (CAS 561-41-1) did not induce gene mutation at the hypoxanthine-guanine phosphoribosyltransferase (Hprt) locus in cultured Chinese Hamster Ovary (CHO) cells in the presence and absence of S9 metabolic activation in an OECD 476 guideline study. Thus, adequate, relevant and reliable studies indicate that the registered substance, 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol (CAS No.: 561-41-1), is non-mutagenic in various in vitro test systems (both in bacterial and mammalian cell cultures). Hence it is concluded that 4,4’-bis(dimethylamino)-4”-(methylamino)trityl alcohol (CAS No.: 561-41-1) is classified as Non-Classified for Germ Cell Mutagenicity according to the Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures (CLP Regulation).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
